Eli Lilly is requesting fast-track approval from the Food and Drug Administration for its Type 2 diabetes medication tirzepatide to be sold as a weight loss drug. The company said that new studies have shown promising results. AACE Treasurer Scott D. Isaacs, MD, FACP, FACE, spoke on CBS Evening News to provide expert health commentary as a leader in the endocrine field and steward of AACE.